We are Napo Therapeutics: an European pharmaceutical company, a young start-up led by a team of experienced professionals. Our mission is to improve the quality of life of people suffering from rare diseases and pathologies with a strong unmet medical need through innovative solutions. Our name reflects our story: The Napo River crosses the territories of the Amazon where the Croton lechleri tree grows – the plant from which we extract the sap that contains a precious active ingredient. We are investigating an innovative and first-in-class drug thanks to the novel mechanism of action of this active ingredient, in order to register it throughout Europe. Right now, our focus is on two serious rare diseases: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD). Napo Therapeutics is a European Company headquartered in Milan. Our majority shareholder is Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, which is headquartered in San Francisco, California and listed on NASDAQ (JAGX).